NEXGEL, Inc. (NXGLW)
| Market Cap | 4.92M -74.6% |
| Revenue (ttm) | 11.42M +31.5% |
| Net Income | -3.00M |
| EPS | -0.38 |
| Shares Out | 8.48M |
| PE Ratio | n/a |
| Forward PE | 1.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 0.0490 |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About NXGLW
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central line... [Read more]
News
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE ...
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa.
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Co...
NexGel appoints Ian Blackman as CFO
NexGel (NXGL) announced the appointment of Ian Blackman as CFO. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerativ...
NEXGEL Transcript: M&A announcement
The acquisition of Celularity's Degenerative Wound segment, backed by Sequence LifeScience, is expected to triple revenue, be immediately accretive, and transform the business into a diversified medical technology platform with strong growth prospects.
NexGel closes acquisition of products from Celularity
NexGel (NXGL) announced the closing of its previously announced license and acquisition of a portfolio of commercial-stage regenerative biomaterials products from Celularity (CELU), a regenerative and...
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET
LANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ul...
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
LANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ul...
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ul...
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ul...
NexGel price target lowered to $2 from $6 at Maxim
Maxim lowered the firm’s price target on NexGel (NXGL) to $2 from $6 and keeps a Buy rating on the shares. The company’s Celularity acquisition could be transformative for NexGel…
NexGel announces terms of agreement of license for products from Celularity
NexGel (NXGL) announced the consideration terms of its previously announced agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (CELU), a...
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio
Celularity reiterates strategic commercialization partnership with NEXGEL
Celularity (CELU) reiterated that its strategic commercialization partnership with NEXGEL (NXGL) is a focused effort by the two companies to rapidly capitalize on renewed regulatory and reimbursement ...
NexGel sign agreement to license, acquire portfolio of products from Celularity
NexGel (NXGL) announced the signing of a definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (CELU), a regenerative and cellul...
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing
NexGel announces financing of $1.797M relating to acquistion
NEXGEL (NXGL) announced the financing of $1.797M relating to a potential acquisition targeted for the first quarter of 2026. The potential acquisition is subject to the completion of due diligence…
NexGelRx receives additional investment from Eric Gruntfest, Ariel Imas
NEXGEL (NXGL) announced that NexGelRx, the Company’s previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of ...
NexGel to spin-off drug delivery program into NexGelRx
NEXGEL (NXGL) announced the spin-off of select drug delivery application assets into NexGelRx, an entity which will focus exclusively on developing and commercializing prescription drug delivery solut...
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off
NEXGEL Earnings Call Transcript: Q3 2025
Q3 2025 revenue was flat year-over-year at $2.9M, but gross margin improved to 42.4% and adjusted EBITDA loss narrowed. Strong contract manufacturing and new product launches are expected to drive a record Q4, with full-year revenue guidance of $12M–$12.5M.
NEXGEL Reports Third Quarter 2025 Financial Results
LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ult...
NEXGEL Transcript: LD Micro Main Event XIX Investor Conference
Significant growth achieved through strategic partnerships, acquisitions, and innovative hydrogel products. Expansion into new markets and product lines, strong revenue growth, and robust R&D pipeline position the company for continued success.
NEXGEL Earnings Call Transcript: Q2 2025
Q2 2025 saw revenue double year-over-year to $2.9M, with gross margin rising to 43.6% and narrowing losses. Strong growth in both contract manufacturing and consumer products, expanded partnerships, and new product launches support reaffirmed 2025 guidance for $13M revenue and positive EBITDA.
NEXGEL to Report Second Quarter 2025 Financial Results on August 12th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.